Company Basilea Pharmaceutica AG OTC Markets

Equities

BPMUF

CH0011432447

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for Basilea Pharmaceutica AG

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:51:48 2024-05-20 pm EDT			5-day change	1st Jan Change
48.15 ^USD	+8.32%		0.00%	+17.44%

May. 16	Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales	MT
May. 16	Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	DJ

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.

Number of employees: 147

CHF in Million	2022	Weight	2023	Weight	Delta
Innovative Pharmaceutical Products 100.0 %	148	100.0 %	158	100.0 %	+6.68%

CHF in Million	2022	Weight	2023	Weight	Delta
Ireland 43.6 %	41	27.9 %	69	43.6 %	+66.34%
Japan 37.8 %	64	43.3 %	60	37.8 %	-6.87%
Uruguay 6.5 %	7	5.0 %	10	6.5 %	+37.84%
United States 3.9 %	10	6.6 %	6	3.9 %	-37.76%
Sweden 2.5 %	3	2.2 %	4	2.5 %	+21.87%
Canada 2.3 %	3	1.9 %	4	2.3 %	+28.57%
China 1.5 %	-	-	2	1.5 %	-
Jordan 1.1 %	3	1.8 %	2	1.1 %	-33.33%
Switzerland 0.9 %	2	1.6 %	1	0.9 %	-41.67%

Managers	Title	Age	Since
David Veitch CEO	Chief Executive Officer	59	14-08-31
Adesh Kaul DFI	Director of Finance/CFO	50	08-12-31
Gerrit Hauck CTO	Chief Tech/Sci/R&D Officer	60	18-04-30
Marc Engelhardt CTO	Chief Tech/Sci/R&D Officer	60	09-12-31
Laurenz Kellenberger CTO	Chief Tech/Sci/R&D Officer	57	99-12-31
Peer Nils Schröder IRC	Investor Relations Contact	-	-
Damian Heller LAW	General Counsel	58	14-12-31
Ursula Eberhardt HRO	Human Resources Officer	62	05-12-31

Members of the board	Title	Age	Since
Nicole Onetto BRD	Director/Board Member	71	17-04-26
Leonard Kruimer BRD	Director/Board Member	66	21-12-31
Alf Gunnar Martin Nicklasson BRD	Director/Board Member	69	13-04-08
Domenico Scala CHM	Chairman	59	11-11-28
Carole A. Sable BRD	Director/Board Member	62	23-04-26
Thomas Werner BRD	Director/Board Member	68	11-11-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	13,169,749	12,064,259 ( 91.61 %)	1,098,157 ( 8.338 %)	91.61 %

Name	Equities	%	Valuation
BASILEA PHARMACEUTICA AG 8.332 %	1,091,643	8.332 %	47 M $
Black Creek Investment Management, Inc. 5.066 %	663,670	5.066 %	29 M $
CI Investments, Inc. 4.901 %	642,065	4.901 %	28 M $
Braginsky Family Office AG 2.990 %	391,677	2.990 %	17 M $
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 2.540 %	332,721	2.540 %	14 M $
Argenta Spaarbank NV 0.7119 %	93,267	0.7119 %	4 M $
Bank J. Safra Sarasin AG (Investment Management) 0.5647 %	73,989	0.5647 %	3 M $
Saint Olive Gestion SNC 0.5152 %	67,500	0.5152 %	3 M $
Mandarine Gestion SA 0.2633 %	34,500	0.2633 %	1 M $
Apo Asset Management GmbH 0.2405 %	31,511	0.2405 %	1 M $

Name	Equities	%	Valuation
BASILEA PHARMACEUTICA AG 8.33%	1,091,643	8.33%	47,015,099 $

Basilea Pharmaceutica AG

Hegenheimermattweg 167b

4123, Allschwil

+41 61 606 11 11

http://www.basilea.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

44.3 CHF

Average target price

70.58 CHF

Spread / Average Target

+59.33%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research